BeiGene, Ltd. (BGNE)
Pre-Market:
| Previous Close | 256.00 |
| Open | 258.73 |
| Bid | 0.00 x 800 |
| Ask | 270.00 x 800 |
| Day's Range | 248.60 - 260.00 |
| 52 Week Range | 118.18 - 280.62 |
| Volume | |
| Avg. Volume | 271,232 |
| Market Cap | 27.014B |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
- Zacks
What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- Motley Fool
Why Shares of BeiGene Were Up Wednesday
Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday. BeiGene didn't make any big announcements, and its earnings report was back on Nov. 9, so the move was curious. Most likely, it was just a little bit of a return to normalcy after the stock took a beating when there were protests in China regarding the country's strict lockdown "zero tolerance" provisions regarding COVID-19.
